Brief: Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251

Dyne Therapeutics

03/09/2024 11:49

Sept 3 (Reuters) - Dyne Therapeutics Inc  DYN.O :
    * DYNE THERAPEUTICS ANNOUNCES NEW CLINICAL DATA FROM PHASE
1/2
DELIVER TRIAL OF DYNE-251 IN DUCHENNE MUSCULAR DYSTROPHY
DEMONSTRATING UNPRECEDENTED DYSTROPHIN EXPRESSION AND FUNCTIONAL
IMPROVEMENT IN MULTIPLE COHORTS
    * DYNE THERAPEUTICS INC - TO PROVIDE REGISTRATION UPDATE BY
YEAR-END
    * DYNE THERAPEUTICS INC - INITIATING REGISTRATIONAL COHORTS
WITH
UPDATE ON PATH TO REGISTRATION BY YEAR-END 2024
    * DYNE THERAPEUTICS INC - DYNE-251 DEMONSTRATES FAVORABLE
SAFETY
PROFILE

Source text for Eikon:  ID:nGNX3mL3gQ 
Further company coverage:  DYN.O 

 ((Reuters.Briefs@thomsonreuters.com;))